Mentor Capital to Discuss Major Cancer Funding, Low PE and Warrant Call at April 29 Shareholder Meeting
(firmenpresse) - SAN DIEGO, CA -- (Marketwire) -- 03/28/12 -- Mentor Capital, Inc. (PINKSHEETS: MNTR) will hold its annual shareholders' meeting at the company offices outside of San Diego, April 29, 2012 at 10:00AM. A management report and director ballots are being mailed to shareholders of record to elect the new board for the upcoming term.
Management discussion focuses on the recent major Mentor investment purchase in melanoma vaccine developer AGI Biopharmaceuticals for $4.7 Million and acquisition of 50% interest in Brighter Day Health for $5.0 Million which is expanding its multi-state telemedicine business. Additional progress on expected very significant additional medical related acquisitions will be reported upon if those acquisitions are announced timely.
Financial highlights previously reported will be outlined including the current $3 per share in cancer and medical assets and the trailing twelve month diluted after-tax earnings per share of $0.17 per share which calculates to a trailing PE of 1.4x. Mentor Capital closed April 28, 2012 at $0.24 per share.
By this announcement, Mentor Capital also is notifying the close of the call period for any remaining Series A warrants at a strike price of $0.09 per share. Such exercise must be completed by May 1, 2012 at 11:59 pm, or the warrants will be redeemed by the company or its designees. Additional detail will be available at the company website and a separate mailing will be supplied to each remaining holder.
Mentor Capital, Inc. is a public company with $125 Million in freely tradable warrants already held by its shareholders. Mentor pledges the proceeds of those warrants to acquire and invest in leading-edge cancer companies and those medical companies that promote the reduction in cost of delivering cancer treatment. Detailed and historic company financial reports and additional important relevant information is presented at .
For further information contact:
Chester Billingsley
CEO
Mentor Capital, Inc.
(760) 788 - 4700
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 28.03.2012 - 12:56 Uhr
Sprache: Deutsch
News-ID 129368
Anzahl Zeichen: 0
contact information:
Town:
SAN DIEGO, CA
Kategorie:
Health & Nutrition
Diese Pressemitteilung wurde bisher 223 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Mentor Capital to Discuss Major Cancer Funding, Low PE and Warrant Call at April 29 Shareholder Meeting"
steht unter der journalistisch-redaktionellen Verantwortung von
Mentor Capital, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
